Confronto

Dulaglutide vs. VK2735

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Metabolico

N. CAS

923950-08-7

nessun dato

Peso molecolare

59670 g/mol

nessun dato

Emivita

110 h

nessun dato

Sequenza

GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-Fc

nessun dato

Meccanismo d'azione

Dulaglutide

Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Dulaglutide	VK2735
Germania	Su prescrizione	Non approvato
JP	Su prescrizione	—
Stati Uniti	Su prescrizione	Non approvato

Voci complete

Frequently asked questions

What is the difference between Dulaglutide and VK2735?: Dulaglutide is classified as "Metabolico", while VK2735 is classified as "Metabolico". Dulaglutide: GLP-1 receptor agonist designed as a fusion protein of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc fragment. FDA-approved 2014 (Trulicity) for type 2 diabetes; EMA approval 2014. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Dulaglutide or VK2735?: The highest available evidence level is "RCT sull'uomo" for Dulaglutide and "RCT sull'uomo" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Dulaglutide and VK2735 in Germany and the United States?: Germania: Dulaglutide — Su prescrizione, VK2735 — Non approvato. Stati Uniti: Dulaglutide — Su prescrizione, VK2735 — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

Dulaglutide

VK2735

Germania

Su prescrizione

Non approvato

Su prescrizione

—

Stati Uniti

Su prescrizione

Non approvato

Frequently asked questions

What is the difference between Dulaglutide and VK2735?

Dulaglutide is classified as "Metabolico", while VK2735 is classified as "Metabolico". Dulaglutide: GLP-1 receptor agonist designed as a fusion protein of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc fragment. FDA-approved 2014 (Trulicity) for type 2 diabetes; EMA approval 2014. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Dulaglutide or VK2735?

The highest available evidence level is "RCT sull'uomo" for Dulaglutide and "RCT sull'uomo" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Dulaglutide and VK2735 in Germany and the United States?

Germania: Dulaglutide — Su prescrizione, VK2735 — Non approvato. Stati Uniti: Dulaglutide — Su prescrizione, VK2735 — Non approvato. These are factual summaries with source and review date on the individual pages.